PIK3CA signaling and pancreatic cancer

PIK3CA 信号传导与胰腺癌

基本信息

  • 批准号:
    10722155
  • 负责人:
  • 金额:
    $ 22.06万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-07-08 至 2025-06-30
  • 项目状态:
    未结题

项目摘要

The goal of this proposal is to explore how to target PIK3CA signaling for treatment of pancreatic ductal adenocarcinoma (PDAC). This deadly cancer is highly resistant to current treatment regimens, including immunotherapy with checkpoint inhibitors. More than 90% of PDAC have oncogenic mutations in KRAS, and PIK3CA is a direct effector of KRAS. Our group first reported that genetic ablation of PIK3CA in the pancreas completely protected mice against oncogenic KRAS-induced tumor formation, and subsequently reported that PIK3CA plays a critical role in sustaining pancreatic tumors by shielding them from the immune system. Orthotopic implantation of KrasG12D;Trp53R172H;Pdx1-Cre (KPC) pancreatic tumor cells in immunocompetent mice caused 100% lethality, whereas mice implanted with Pik3ca-/- KPC (PIK3CA-KO) KPC cells exhibited tumor regression with 100% animal survival. A genome-wide gene deletion screen to search for molecules that can reverse the elimination of PIK3CA-KO cells by the immune system identified PCCB, which catalyzes the carboxylation of propionyl-CoA to produce methylmalonyl-CoA. PCCB-null PIK3CA-KO KPC cells were generated, and when implanted in mice, these tumors were not cleared by the host immune system. Two hypotheses will be tested: 1) Oncogenic KRAS activation of PIK3CA modulates a PCCB-regulated metabolic environment that favors evasion of pancreatic cancer from immune elimination; and 2) Alpelisib inhibition of PIK3CA enhances the activity of anti-PD1 plus anti-PCSK9 therapy against pancreatic tumors. Aim 1 investigates mechanisms by which KRAS activation of PIK3CA modulates a PCCB-regulated metabolic environment that favors immune evasion of pancreatic cancer, including upregulation of immune checkpoints and T cell exhaustion. Tumor infiltrating T cells will be isolated and analyzed by single-cell RNA and T cell receptor (TCR) V(D)J sequencing, flow cytometry and IHC. Adoptive T cell transfer experiments will be performed to determine if T cells previously exposed to PCCB-null PIK3CA-KO tumors will eliminate PIK3CA- KO tumors implanted in SCID mice. Cell metabolism and immunological profile of PCCB-null PIK3CA-KO vs. PIK3CA-KO and parental KPC cell lines will be measured to better understand the metabolic alterations controlled by PIK3CA and PCCB and how these changes may lead to immune suppression. Aim 2 is a therapeutic study that tests the efficacy of alpelisib, a PIK3CA inhibitor, in combination with neutralizing antibodies against PD-1 and PCSK9 for treatment of pancreatic cancer using the orthotopically implanted KPC mouse model. Tumor infiltrating T cells will also be isolated and analyzed by single-cell sequencing. In summary, this proposal will investigate how PIK3CA signaling regulates the metabolic and immunological profile of pancreatic cancer. Alpelisib, anti-PD1 antibodies and anti-PCSK9 antibodies are all FDA-approved for clinical use. Successful completion of our studies may lead to clinical trials with these approved drugs for treatment of pancreatic cancer.
该提案的目标是探索如何靶向PIK 3CA信号传导来治疗胰管疾病 腺癌(PDAC)。这种致命的癌症对目前的治疗方案具有高度耐药性,包括 检查点抑制剂的免疫疗法。超过90%的PDAC在KRAS中存在致癌突变, PIK 3CA是KRAS的直接效应子。我们的小组首次报道了胰腺中PIK 3CA的基因切除, 完全保护小鼠免受致癌KRAS诱导的肿瘤形成,随后报道, PIK 3CA通过保护胰腺肿瘤免受免疫系统的影响,在维持胰腺肿瘤方面发挥着关键作用。 KrasG 12 D; Trp 53 R172 H; Pdx 1-Cre(KPC)胰腺肿瘤细胞在免疫活性细胞中的原位植入 小鼠引起100%致死率,而植入Pik 3ca-/- KPC(PIK 3CA-KO)KPC细胞的小鼠表现出 肿瘤消退,100%动物存活。全基因组基因缺失筛选,以寻找分子, 可以逆转免疫系统识别的PCCB对PIK 3CA-KO细胞的消除,PCCB催化PIK 3CA-KO细胞的增殖。 丙酰-CoA羧化以产生甲基丙二酰-CoA。PCCB-无效的PIK 3CA-KO KPC细胞是 当植入小鼠体内时,这些肿瘤不会被宿主免疫系统清除。两 将检验以下假设:1)PIK 3CA的致癌性KRAS激活调节PCCB调节的代谢 有利于胰腺癌逃避免疫消除的环境;和2)Alpelisib抑制胰腺癌的免疫消除。 PIK 3CA增强抗PD 1加抗PCSK 9疗法对胰腺肿瘤的活性。要求1 研究KRAS激活PIK 3CA调节PCCB调节的代谢的机制 有利于胰腺癌免疫逃避的环境,包括免疫检查点的上调 和T细胞衰竭。肿瘤浸润性T细胞将被分离并通过单细胞RNA和T细胞免疫印迹分析。 受体(TCR)V(D)J测序、流式细胞术和IHC。T细胞转移实验将在 进行以确定先前暴露于PCCB-无效PIK 3CA-KO肿瘤的T细胞是否将消除PIK 3CA。 移植到SCID小鼠中的KO肿瘤。PCCB-无效PIK 3CA-KO相对于PIK 3CA-KO的细胞代谢和免疫学特征 将测量PIK 3CA-KO和亲本KPC细胞系,以更好地了解代谢改变 PIK 3CA和PCCB控制以及这些变化如何导致免疫抑制。目标2是一个 一项测试alpelisib(一种PIK 3CA抑制剂)与中和药物联合治疗的疗效的治疗性研究 使用原位植入的KPC治疗胰腺癌的针对PD-1和PCSK 9的抗体 小鼠模型还将分离肿瘤浸润性T细胞并通过单细胞测序进行分析。在 总之,本提案将研究PIK 3CA信号传导如何调节代谢和免疫 胰腺癌的症状Alpelisib、抗PD 1抗体和抗PCSK 9抗体均为FDA批准的用于治疗癌症的药物。 临床应用。成功完成我们的研究可能会导致这些获批药物的临床试验, 胰腺癌的治疗

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RICHARD Z LIN其他文献

RICHARD Z LIN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RICHARD Z LIN', 18)}}的其他基金

The role of PI3K in pancreatic cancer genetics and progression
PI3K 在胰腺癌遗传学和进展中的作用
  • 批准号:
    10266023
  • 财政年份:
    2018
  • 资助金额:
    $ 22.06万
  • 项目类别:
PI3K signaling and channelopathies in the heart
心脏中的 PI3K 信号传导和通道病
  • 批准号:
    9295021
  • 财政年份:
    2016
  • 资助金额:
    $ 22.06万
  • 项目类别:
Mouse model to study dependence of pancreatic cancer on Pik3ca for progression
研究胰腺癌对 Pik3ca 进展依赖性的小鼠模型
  • 批准号:
    9188056
  • 财政年份:
    2015
  • 资助金额:
    $ 22.06万
  • 项目类别:
Decreased PI3K Signaling and Long QT Syndrome in Diabetes
糖尿病患者 PI3K 信号传导减弱和长 QT 综合征
  • 批准号:
    8762239
  • 财政年份:
    2013
  • 资助金额:
    $ 22.06万
  • 项目类别:
Decreased PI3K Signaling and Long QT Syndrome in Diabetes
糖尿病患者 PI3K 信号传导减弱和长 QT 综合征
  • 批准号:
    8544539
  • 财政年份:
    2013
  • 资助金额:
    $ 22.06万
  • 项目类别:
Decreased PI3K Signaling and Long QT Syndrome in Diabetes
糖尿病患者 PI3K 信号传导减弱和长 QT 综合征
  • 批准号:
    8966666
  • 财政年份:
    2013
  • 资助金额:
    $ 22.06万
  • 项目类别:
Gq-coupled Receptors Inhibit PI 3-kinase/Akt Signaling Pathway
Gq 偶联受体抑制 PI 3 激酶/Akt 信号通路
  • 批准号:
    8003647
  • 财政年份:
    2009
  • 资助金额:
    $ 22.06万
  • 项目类别:
Gq-coupled Receptors Inhibit PI 3-kinase/Akt Signaling Pathway
Gq 偶联受体抑制 PI 3 激酶/Akt 信号通路
  • 批准号:
    7525551
  • 财政年份:
    2002
  • 资助金额:
    $ 22.06万
  • 项目类别:
Gq-coupled Receptors Inhibit PI 3-kinase/Akt Signaling Pathway
Gq 偶联受体抑制 PI 3 激酶/Akt 信号通路
  • 批准号:
    7645586
  • 财政年份:
    2002
  • 资助金额:
    $ 22.06万
  • 项目类别:
Gq-Coupled Receptors Inhibit PI 3-Kinase/Akt Signaling Pathway
Gq 偶联受体抑制 PI 3 激酶/Akt 信号通路
  • 批准号:
    8064263
  • 财政年份:
    2002
  • 资助金额:
    $ 22.06万
  • 项目类别:

相似海外基金

The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
  • 批准号:
    EP/Z000920/1
  • 财政年份:
    2025
  • 资助金额:
    $ 22.06万
  • 项目类别:
    Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
  • 批准号:
    FT230100276
  • 财政年份:
    2024
  • 资助金额:
    $ 22.06万
  • 项目类别:
    ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
  • 批准号:
    MR/X024261/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.06万
  • 项目类别:
    Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
  • 批准号:
    DE240100388
  • 财政年份:
    2024
  • 资助金额:
    $ 22.06万
  • 项目类别:
    Discovery Early Career Researcher Award
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
  • 批准号:
    2232190
  • 财政年份:
    2023
  • 资助金额:
    $ 22.06万
  • 项目类别:
    Continuing Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
  • 批准号:
    2337595
  • 财政年份:
    2023
  • 资助金额:
    $ 22.06万
  • 项目类别:
    Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
  • 批准号:
    23K17514
  • 财政年份:
    2023
  • 资助金额:
    $ 22.06万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Analysis of thermoregulatory mechanisms by the CNS using model animals of female-dominant infectious hypothermia
使用雌性传染性低体温模型动物分析中枢神经系统的体温调节机制
  • 批准号:
    23KK0126
  • 财政年份:
    2023
  • 资助金额:
    $ 22.06万
  • 项目类别:
    Fund for the Promotion of Joint International Research (International Collaborative Research)
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
  • 批准号:
    2842926
  • 财政年份:
    2023
  • 资助金额:
    $ 22.06万
  • 项目类别:
    Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
  • 批准号:
    NC/X001644/1
  • 财政年份:
    2023
  • 资助金额:
    $ 22.06万
  • 项目类别:
    Training Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了